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Abstract
Background—Echocardiographic indices of cardiac structure and function and natriuretic
peptide levels are strong predictors of mortality in patients with heart failure. Whether cardiac
ultrasound and natriuretic peptides provide independent prognostic information is uncertain.
Methods—Echocardiograms and measurements of N-terminal pro-B type natriuretic peptide
(NT-proBNP) were prospectively performed in 211 patients with left ventricular systolic
dysfunction who were followed for a median of 4 years. Echocardiographic variables and NT-
proBNP were examined as predictors of all-cause mortality in univariable and multivariable
proportional hazards models.
Results—Participants averaged 57 (SD 12) years of age and had a mean left ventricular ejection
fraction of 32 (SD 11) %. A total of 71 patients (34%) died during the follow-up period. NT-
ProBNP was a strong predictor of mortality (P < 0.001) as were multiple echocardiographic
measures. In models that included age and NT-proBNP, with other clinical variables eligible for
entry by stepwise selection, significant predictors of death included left ventricular ejection
fraction (P = 0.013) and end-diastolic volume (P < 0.001), left atrial volume index (P = 0.005),
right atrial volume index (P = 0.003), and tricuspid regurgitation area (P = 0.015). In models that
also included left ventricular ejection fraction, end-diastolic volume of the left ventricle (P =
0.019), left atrial volume (P = 0.026), and right atrial volume (P = 0.020) remained significant
predictors of mortality.
Conclusions—Left ventricular size and function and left atrial and right atrial sizes are
significant predictors of all-cause mortality in patients with heart failure, independent of NT-
proBNP levels and other clinical variables.
Echocardiography is an important tool in the evaluation of patients with heart failure. A
comprehensive two-dimensional and Doppler echocardiogram provides a reliable
assessment of left ventricular and right ventricular function and of the severity of associated
valvular lesions. In addition to providing insight into the etiology of heart failure,
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echocardiographic data is valuable in assessing prognosis. The degree of left ventricular
remodeling1,2, left ventricular dysfunction2,3,4, impaired left ventricular filling1,3, left atrial
enlargement5, right ventricular dysfunction6,7, and mitral and tricuspid regurgitation1,8,9 are
all predictors of adverse outcomes.
Recent studies have demonstrated that B type natriuretic peptide (BNP) and its precursor, N-
terminal proBNP (NT-proBNP), are strong predictors of morbidity and mortality in patients
with chronic heart failure.10 Whether echocardiography provides incremental prognostic
information is uncertain. The objective of this study was to assess the prognostic utility of
widely available echocardiographic parameters after accounting for age, NT-proBNP levels,
and other predictors of mortality in patients with heart failure and severe left ventricular
dysfunction.
METHODS
This is a prospective observational study of clinically stable patients with heart failure and
left ventricular dysfunction. Baseline demographic and clinical parameters, NT-proBNP
levels, and echocardiographic measures were examined as predictors of all-cause mortality
and other adverse outcomes over a median follow-up interval of 4 years. The study was
approved by the Institutional Review Board at Duke University Medical Center, and written
informed consent was obtained from all participants prior to their participation.
Patients
The study sample consisted of 211 consecutive patients recruited from the heart failure
clinics at Duke University Medical Center and the University of North Carolina at Chapel
Hill from January, 2000 through December, 2002. Inclusion criteria included left ventricular
ejection fraction ≤ 40% by angiography, radionuclide ventriculography, or
echocardiography within the past year; and clinically stable heart failure (i.e., not requiring
hospitalization or medication adjustment for decompensation for at least 3 months).
Exclusion criteria included myocardial infarction, percutaneous coronary intervention, or
coronary artery bypass graft surgery in the past 3 months; and uncontrolled hypertension.
Baseline assessments, measurement of NT-proBNP, and echocardiography were performed
at the time of enrollment on a single visit to the research laboratory.
Baseline assessments
Demographic and clinical characteristics and medication use were determined by interview
and examination of the medical record. Height, weight, and blood pressure were measured
on the visit to the research laboratory. Blood specimens were acquired for measurement of
serum sodium, hematocrit, and creatinine; glomerular filtration rate was estimated using the
abbreviated Modification of Diet in Renal Disease (MDRD) formula.
NT-proBNP
Blood was collected from the antecubetal vein in a phlebotomy tube containing EDTA,
centrifuged at 1000Xg for 10 minutes, and stored at −80°C. Samples were thawed within 12
months of collection for measurements of NT-proBNP using an electrochemiluminescence
immunoassay (Elecsys proBNP, Roche Diagnostics Corporation, Indianapolis, IN).
According to the manufacturer, NT-proBNP values are 10% lower in samples collected in
EDTA tubes compared to serum or heparinized plasma.
Echocardiography
Echocardiograms were performed by a single sonographer using a defined imaging protocol,
and were stored as digital loops. Two-dimensional images and Doppler flow tracings were
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subsequently analyzed by an experienced echocardiographer who had no knowledge of
patient clinical outcomes, using customized offline software (Access Point 2000, Freeland
Systems, LLC, Westfield, Indiana). Measurements were made on 3 representative beats and
the results were averaged.
The following indices of left ventricular and right ventricular size and function, left atrial
and right atrial sizes, left ventricular filling, and mitral and tricuspid regurgitation were
measured: 1) left ventricular ejection fraction was determined using the biplane Simpson’s
rule from apical 4-chamber and 2-chamber images of the heart.11 In patients in whom poor
endocardial definition precluded quantification of left ventricular volumes (n = 43 ), ejection
fraction was estimated visually. 2) Left ventricular end-diastolic volume was determined by
the biplane Simpson’s rule, as described above. 3) Right ventricular function was quantified
as the tricuspid annulus systolic excursion, measured as the difference between the distances
from the right ventricular apex to the lateral tricuspid annulus at end-diastole and at end-
systole.6 4) Left atrial volume was estimated by using the biplane area-length formula after
determining the end-systolic areas and long axis lengths of the left atrium in the apical 4-
chamber and 2-chamber views.11 5) Right atrial volume was calculated using the single-
plane area-length method after right atrial area and long-axis length were measured in the
apical 4-chamber view.11 6) Mitral regurgitation severity was quantified as the maximum
area of the regurgitant color flow Doppler jet in the apical 2-chamber and 4-chamber views.
7) Tricuspid regurgitation severity was estimated as the maximum area of the regurgitant
color flow Doppler jet in the apical 4 chamber view. 8) Deceleration time of early left
ventricular filling was measured by pulsed wave Doppler, with the sample volume located at
the tip of the mitral valve leaflets. Left ventricular end-diastolic volume and left atrial and
right atrial volumes were indexed for body size by dividing by body surface area (BSA).
Follow-up
Each patient’s medical record was reviewed annually on anniversaries of the baseline
assessment by trained research assistants. Deaths were verified through hospital and
Emergency Medical Service records, and the cause of death was determined by consensus of
at least 3 study physicians. The median follow-up was 4 years with a range of 3–6 years.
Follow-up data were available for all participants.
Analysis of Data
All analyses were performed using SAS statistical software, version 9.1. Data were
summarized as mean (SD) for continuous variables and number of patients (%) for
categorical variables.
The primary endpoint was all-cause mortality. Secondary endpoints included death from
progressive heart failure, sudden cardiac death, and a composite endpoint of death or cardiac
transplant. Cox proportional hazards modeling was used for univariable analyses of
echocardiographic variables as predictors of endpoints. Each echocardiographic variable
was then examined in multivariable models that included age and NT-proBNP; other
variables of potential explanatory value, including gender, body mass index, etiology of
heart failure (ischemic or nonischemic), history of atrial fibrillation, New York Heart
Association functional class, diabetes, systolic blood pressure, heart rate, glomerular
filtration rate, serum sodium, hematocrit, and QRS duration, were eligible for entry into the
models by stepwise selection (significance level for entry into the model = 0.1).
Echocardiographic variables that were independently predictive of adverse outcomes in
these multivariable models were further evaluated in models incorporating the same
variables plus left ventricular ejection fraction. Hazard ratios (HR) and their corresponding
95% confidence intervals (95% CI) were produced from the parameter estimates and
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standard errors obtained from the proportional hazards models. For Cox proportional
hazards models, NT-proBNP values were trimmed at the 95th percentile.
RESULTS
Baseline demographic and clinical characteristics of the patients have been described
previously12 and are summarized in Table I. Mean values for echocardiographic parameters
are shown in Table II. The average age of study participants was 57 (SD 12) years, with a
range of 27–88 years. Heart failure was due to coronary artery disease in 43%. Most had
New York Heart Association functional class II or III heart failure at enrollment.
Hypertension and diabetes were common co-morbidities. The vast majority were treated
with a beta blocker and either an angiotensin converting enzyme inhibitor or angiotensin
receptor blocker. The mean NT-proBNP was 1675 (SD 2657) pg/ml, with a median value of
693 pg/ml. The left ventricular ejection fraction averaged 32 (SD 11)%. Seventeen subjects
(8%) had an implantable defibrillator at the time of enrollment, and an additional 63 (30%)
had a device implanted during the follow-up period.
During the follow-up period, 71 patients (34%) died; 23 died of progressive heart failure, 31
died suddenly, 2 died of other cardiac causes, and 15 died of noncardiac causes. Twelve
(6%) underwent a cardiac transplant.
As shown in Table III, when examined as univariable predictors, left ventricular volume and
ejection fraction, deceleration time, right ventricular function, left atrial and right atrial
volumes, and severity of mitral regurgitation and tricuspid regurgitation were all
significantly associated with all-cause mortality. NT-proBNP was also a strong predictor of
mortality (HR = 2.02, 95% CI = 1.65 – 2.48, P < 0.001, for a 2,000 pg/ml change in NT-
proBNP). To determine if echocardiographic measures added incremental prognostic value,
models including age, NT-proBNP, and individual echocardiographic parameters, with other
clinical variables eligible for entry by stepwise selection, were examined (Table IV). Left
ventricular ejection fraction and end-diastolic volume, left atrial and right atrial volumes,
and tricuspid regurgitation area were significant predictors of death. In models that also
included left ventricular ejection fraction, end-diastolic left ventricular volume (HR = 1.22,
95% CI = 1.04–1.43, P = 0.019 for an increase of 25 ml/m2), left atrial volume (HR = 1.29,
95% CI = 1.03–1.62, P = 0.026 for an increase of 20 ml/m2), and right atrial volume (HR =
1.41, 95% CI = 1.06–1.89, P = 0.020 for an increase of 20 ml/m2) remained significant
predictors of mortality.
Echocardiographic measures were stronger predictors of death from heart failure than of
sudden cardiac death. When death from heart failure was considered as the endpoint, left
ventricular ejection fraction, left ventricular end-diastolic volume index, deceleration time,
mitral regurgitation area, left atrial volume index, and right atrial volume index were all
significant predictors of an adverse outcome in multivariable analyses, while only left
ventricular ejection fraction and right atrial volume index were independent predictors of
sudden cardiac death. When a composite endpoint of death or cardiac transplant was
considered, all echocardiographic variables except the tricuspid annular excursion were
significant predictors in multivariable models.
DISCUSSION
In our cohort of outpatients with stable heart failure, echocardiographic measurements of
ejection fraction, left ventricular end-diastolic volume, left and right atrial volumes, and
severity of tricuspid regurgitation were predictive of mortality after adjusting for NT-
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proBNP and other clinical variables; and left ventricular, left atrial, and right atrial volumes
remained significant predictors in models that also included left ventricular ejection fraction.
These findings reaffirm decades of research demonstrating the prognostic importance of left
ventricular function and geometry in patients with heart failure. Although ejection fraction is
influenced by loading conditions and is difficult to measure, an inverse relationship between
this index of systolic function and cardiovascular mortality has been demonstrated over a
wide range of severities of heart failure.2,3,4 Similarly, the degree of left ventricular
remodeling has consistently correlated with mortality in cohorts of patients with heart
failure.1,2
More recently, left atrial enlargement has been recognized as a robust predictor of adverse
cardiovascular outcomes.5,13 Left atrial size increases in response to chronically elevated
left ventricular filling pressures. As a reflection of left ventricular diastolic function over
time, left atrial volume has theoretical advantages over load-dependent Doppler indices of
instantaneous filling properties and the “snap-shot” view of left ventricular stretch provided
by natriuretic peptides. Our observations suggest that right atrial volume may similarly be
predictive of death in patients with heart failure.
Several previous studies have compared the prognostic values of natriuretic peptides and
cardiac ultrasound in patients hospitalized with heart failure. Gackowski, et al,14 performed
serial echocardiograms and measurements of BNP in patients hospitalized with acute heart
failure. Serial BNP measurements were more informative than repeated echocardiograms in
predicting adverse cardiac events over the 60 days following admission. Dokainish, et al,15
measured BNP and two-dimensional echocardiographic parameters in patients at the time of
hospital discharge. A BNP >250 pg/ml predicted 41 of 54 cardiovascular deaths or
hospitalizations for heart failure over a mean follow-up of 527 days, while high risk
echocardiographic features predicted 51 of 54 events (p = 0.51). BNP was more cost
effective than echocardiography. Dokainish, et al,16 also reported that predischarge BNP and
mitral annular tissue Doppler velocities were independent predictors of death or
rehospitalization, while other more conventional echocardiographic parmeters, such as
ejection fraction, left ventricular end-diastolic volume, left atrial volume, and deceleration
time, were not predictive of adverse events in multivariable analyses. We are not aware of
previous studies that have examined the incremental prognostic values of echocardiography
and natriuretic peptide levels in outpatients with stable heart failure.
In summary, cardiac ultrasound and natriuretic peptide levels provide important prognostic
information in patients with stable, advanced heart failure. Echocardiographic measures of
left ventricular size and function and of left atrial and right atrial sizes are significant
predictors of mortality, independent of NT-proBNP levels and other clinical variables.
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Table I
Clinical features of the study cohort
Age (yrs) 57 (12)
Male gender (n [%]) 144 (69)
Ethnicity
 African American (n [%] ) 101 (48)
 Caucasian (n [%] ) 98 (47)
 Other (n [%] ) 12 (6)
Body mass index (kg/m2) 31.2 (7.2)
Ischemic cardiomyopathy (n [%] ) 91 (43)
New York Heart Association class
 I (n [%] ) 6 (3)
 II (n [%] ) 119 (56)
 III (n [%] ) 82 (39)
 IV (n [%] ) 4 (2)
Diabetes (n [%]) 93 (44)
Hypertension (n [%]) 162 (77)
Hypercholesterolemia (n [%]) 104 (49)
History of atrial fibrillation (n [%]) 40 (19)
Current smoker (n [%]) 36 (17)
Systolic blood pressure (mmHg) 100 (18)
Diastolic blood pressure (mmHg) 61 (11)
Heart rate (bpm) 67 (12)
Glomerular filtration rate (ml/min per 1.73 m2) 67 (28)
Serum sodium (mEq/dl) 139 (3)
Hematocrit (%) 40 (5)
NT-proBNP (pg/ml) 1675 (2657)
QRS duration (ms) 120 (31)
Implantable defibrillator (n [%]) 17 (8)
Medications
 ACE inhibitor (n [%]) 182 (86)
 Angiotensin receptor blocker (n [%]) 16 (8)
 Beta adrenergic receptor blocker (n [%]) 184 (88)
 Aldosterone antagonist (n [%]) 66 (31)
 Hydralazine (n [%]) 10 (5)
 Long-acting nitrate (n [%]) 41 (19)
 Digoxin (n [%]) 147 (70)
 Statin (n [%]) 98 (46)
 Aspirin (n [%]) 110 (52)
Values are expressed as mean (SD) or n (%). ACE = angiotensin converting enzyme; NT-proBNP = N-terminal pro-B type natriuretic peptide.
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Table II
Echocardiographic variables in the study cohort
LV ejection fraction (%) 32 (11)
LV end-diastolic volume index (ml/m2) 70 (39)
Deceleration time (ms) 221 (81)
MR area (cm2) 4.6 (5.1)
LA volume index (ml/m2) 49 (23)
Tricuspid annular excursion (cm) 1.5 (0.6)
TR area (cm2) 2.4 (3.4)
RA volume index (ml/m2) 35 (16)
Values are expressed as mean (SD). LA = left atrial; LV = left ventricular; MR = mitral regurgitation; RA = right atrial; TR = tricuspid
regurgitation.
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Table III
Results of univariable proportional hazards models predicting all-cause mortality: hazard ratios, 95%
confidence intervals, and P values for selected clinical and echocardiographic variables
HR (95% CI) P value
Age (10 yr) 1.17 (0.97–1.42) 0.098
NT-pro BNP (2000 pg/ml) 2.02 (1.65–2.48) <0.001
LV ejection fraction (10%) 0.63 (0.50–0.79) <0.001
LV end-diastolic volume index (25 ml/m2) 1.40 (1.23–1.60) <0.001
Deceleration time (100 ms) 0.65 (0.45–0.95) 0.020
MR area (5 cm2) 1.42 (1.17–1.73) <0.001
LA volume index (20 ml/m2) 1.66 (1.41–1.95) <0.001
Tricuspid annular excursion (0.5 cm) 0.70 (0.57–0.87) 0.001
TR area (5 cm2) 2.00 (1.49–2.75) <0.001
RA volume index (20 ml/m2) 1.78 (1.41–2.24) <0.001
Hazard ratio and confidence interval calculations were based on changes of approximately 1 SD (indicated in parentheses) for continuous variables.
CI = confidence interval; HR = hazard ratio; LA = left atrial; LV = left ventricular; MR = mitral regurgitation; RA = right atrial; TR = tricuspid
regurgitation.
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Table IV
Results of multivariable proportional hazards models predicting all-cause mortality: hazard ratios, 95%
confidence intervals, and P values for models that incorporate age and NT-proBNP, with other clinical
characteristics eligible for entry by stepwise selection
HR (95% CI) P value
LV ejection fraction (10%)a 0.71 (0.54–0.93) 0.013
LV end-diastolic volume index (25 ml/m2)a,b,c 1.39 (1.18–1.64) <0.001
Deceleration time (100 ms)a,d 0.65 (0.42–1.02) 0.059
MR area (5 cm2)a,b 1.15 (0.91–1.45) 0.237
LA volume index (20 ml/m2)d 1.38 (1.10–1.72) 0.005
Tricuspid annular excursion (0.5 cm)a 0.82 (0.64–1.06) 0.123
TR area (5 cm2)a 1.57 (1.09–2.25) 0.015
RA volume index (20 ml/m2)a,d 1.54 (1.16–2.05) 0.003
Hazard ratio and confidence interval calculations were based on changes of approximately 1 SD (indicated in parentheses) for continuous variables.
CI = confidence interval; HR = hazard ratio; LA = left atrial; LV = left ventricular; MR = mitral regurgitation; RA = right atrial; TR = tricuspid
regurgitation.
a
Glomerular filtration rate was selected for inclusion in the model.
b
Heart rate was selected for inclusion in the model.
c
Etiology of heart failure was selected for inclusion in the model.
d
Serum sodium was selected for inclusion in the model.
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